United Therapeutics UTHR UHeart, UKidney, and UThymoKidney — Milestone payment to be made
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept uthr:MilestonePaymentToBeMadeUponCommercialLaunchOfProduct.
The official record: United Therapeutics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about United Therapeutics's uheart, ukidney, and uthymokidney — milestone payment to be made.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is United Therapeutics's uheart, ukidney, and uthymokidney — milestone payment to be made?
- United Therapeutics (UTHR) reported uheart, ukidney, and uthymokidney — milestone payment to be made of $6.25M in Q4 2025.
- How has United Therapeutics's uheart, ukidney, and uthymokidney — milestone payment to be made changed year-over-year?
- United Therapeutics's uheart, ukidney, and uthymokidney — milestone payment to be made decreased by 0.0% year-over-year, from $6.25M to $6.25M.
- What does uheart, ukidney, and uthymokidney — milestone payment to be made mean?
- This represents the total outstanding contractual obligations for future milestone payments related to the development or commercialization of the UHeart, UKidney, and UThymoKidney programs. These payments are typically triggered by the achievement of specific regulatory, clinical, or commercial milestones defined in licensing or collaboration agreements. It serves as a measure of future capital commitments required to maintain rights to these specific organ-related therapeutic assets.